ISRA
VanEck Vectors Israel ETFISRA Fund Description
ISRA tracks a cap-weighted, committee-reviewed index of Israeli and Israeli-linked companies.
ISRA Factset Analytics Insight
ISRA targets Israeli companies of all cap sizes, and attempts to compete head-to-head against the only other Israel-focused fund in the segment, iShares' EIS. While ISRA is cap-weighted, its selection process is unique. Securities are selected based on quantitative and qualitative factors to determine if securities qualify as 'Israeli' or 'Israeli-linked' and finalized by the BlueStar Index Advisory Committee. This explains the fund's exposure outside of Israel, including close to 30% to the US. Notably, any one security is capped at 12.5%. This greatly limits the fund's exposure to generic drug manufacturing giant Teva Pharmaceuticals, and causes ISRA to heavily underweight health care, for better or worse. The fund's 0.59% fee undercuts competitor EIS by 2 bps.
ISRA MSCI ESG Analytics Insight
VanEck Vectors Israel ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.59 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. VanEck Vectors Israel ETF ranks in the 29th percentile within its peer group and in the 9th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
ISRA Charts And Performance
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
ISRA Portfolio Data
ISRA Portfolio Management
ISRA Tax Exposures
ISRA Fund Structure
ISRA Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of ISRA. ISRA is rated a 3 out of 5.
ISRA Tradability
ISRA Sector/Industry Breakdown
ISRA
ISRA Top 10 Holdings[View All]
ISRA Countries
ISRA
ISRA Regions
ISRA
ISRA Economic Development
ISRA
ISRA Performance Statistics
ISRA MSCI ESG Ratings
ISRA Benchmark Comparison Summary
ISRA
ISRA Benchmark Comparison Market Cap Size
ISRA
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.